Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Bristol-Myers Squibb Co.

BMY

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Last trade $60.85
Day change -$2.085 (-3.31%)
Day range $60.70 – $63.20
Volume 8,842,951
Market cap $128.63B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$128.63B
Price / earnings
13.86×
Price / book
5.76×
Price / sales
2.62×
EV / sales
3.31×
EV / EBITDA
10.94×

Profitability

Earnings per share
$4.54
Return on assets
10.59%
Return on equity
41.59%
Dividend yield
3.96%

Liquidity and leverage

Debt / equity
1.93×
Current ratio
1.53×
Quick ratio
1.38×
Cash ratio
0.47×

Cash flow

Price / cash flow
10.06×
Price / free cash flow
11.24×
Free cash flow
$11.44B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BMY, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$12.97B$11.49B$12.5B$12.22B$12.27B$11.2B$12.34B$11.89B
Cost of revenue$3.73B$3.42B$4.1B$3.44B$3.37B$3.03B$4.81B$2.96B
Gross profit$9.25B$8.07B$8.41B$8.79B$8.9B$8.17B$7.53B$8.94B
Selling, general and administrative$1.83B$1.62B$2.18B$1.79B$1.71B$1.58B$2.14B$1.98B
Research and development$2.96B$2.74B$3.98B$3.16B$2.58B$2.45B$3.22B$2.64B
Total operating expenses$5.22B$4.8B$6.99B$5.78B$6.63B$4.86B$7.05B$7.03B
Operating income$4.03B$3.27B$1.42B$3.01B$2.27B$3.31B$480M$1.91B
Interest expense-$407M$0$0$0-$485M$0$0$0
Income before taxes$4.09B$3.24B$1.47B$3.11B$1.77B$2.97B$175M$1.68B
Income taxes$770M$561M$384M$919M$460M$509M$99M$461M
Net income$3.32B$2.68B$1.09B$2.2B$1.31B$2.46B$76M$1.22B
Net income attributable to common shareholders$3.32B$2.68B$1.09B$2.2B$1.31B$2.46B$72M$1.21B
EBITDA$4.62B$3.87B$2.4B$4.02B$4.79B$4.32B$2.36B$4.5B
Basic earnings per share$1.62$1.31$0.53$1.08$0.64$1.21$0.04$0.60
Diluted earnings per share$1.62$1.31$0.53$1.08$0.64$1.20$0.04$0.60

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

The Motley Fool

5 Fantastic Dividend Stocks You May Be Overlooking

The article highlights five underrated dividend stocks offering attractive yields: Ares Capital (9.9% yield, 69 consecutive quarters of maintained/grown dividends), Bristol Myers Squibb (4% yield, 17 consecutive years of increases despite patent cliff concerns), Edison International (5.9% yield, 22 consecutive years of increases but facing wildfire litigation), MPLX LP (8.5% yield with 12.5% annual distribution growth), and NNN REIT (6% yield with 37 consecutive years of dividend increases, outperforming Realty Income).

The Motley Fool

5 Dividend Stocks With High Yields That Are Safer Than You Might Think

The article examines five high-yield dividend stocks that appear riskier than they actually are. Pfizer and Bristol Myers Squibb face normal pharmaceutical industry headwinds from patent expirations but maintain sustainable dividends through strong cash flows. REITs Realty Income and W.P. Carey are pressured by rising interest rates, but historical market adjustments should protect profitability. Hormel Foods, despite slow turnaround progress, has strong financials and backing from the Hormel Foundation, making its dividend safer than its yield suggests.

The Motley Fool

Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.

Bristol Myers Squibb faces upcoming patent expirations on older drugs, particularly Eliquis losing U.S. patent protection in 2028. However, the company's newer growth portfolio is already generating $7.7 billion quarterly in revenue, exceeding the $5.42 billion from legacy drugs. With a 4% dividend yield and reasonable 55% payout ratio, the stock may appeal to aggressive income investors despite near-term patent cliff risks.

The Motley Fool

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Oct 2, 2026$0.63Nov 2, 2026recurring
Jul 2, 2026$0.63Aug 3, 2026recurring
Apr 2, 2026$0.63May 1, 2026recurring
Jan 2, 2026$0.63Feb 2, 2026recurring
Oct 3, 2025$0.62Nov 3, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.